PSI Advisors LLC Has $582,000 Position in Pfizer Inc. (NYSE:PFE)

PSI Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 17.5% during the first quarter, HoldingsChannel reports. The institutional investor owned 22,964 shares of the biopharmaceutical company’s stock after selling 4,859 shares during the quarter. PSI Advisors LLC’s holdings in Pfizer were worth $582,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. State of Alaska Department of Revenue boosted its holdings in shares of Pfizer by 2.3% in the 1st quarter. State of Alaska Department of Revenue now owns 796,553 shares of the biopharmaceutical company’s stock valued at $20,184,000 after purchasing an additional 17,820 shares in the last quarter. CWA Asset Management Group LLC boosted its holdings in shares of Pfizer by 4.0% in the 1st quarter. CWA Asset Management Group LLC now owns 32,184 shares of the biopharmaceutical company’s stock valued at $816,000 after purchasing an additional 1,225 shares in the last quarter. LifeWealth Investments LLC boosted its holdings in shares of Pfizer by 12.0% in the 1st quarter. LifeWealth Investments LLC now owns 15,679 shares of the biopharmaceutical company’s stock valued at $397,000 after purchasing an additional 1,678 shares in the last quarter. JBR Co Financial Management Inc acquired a new stake in shares of Pfizer in the 1st quarter valued at $201,000. Finally, Kingswood Wealth Advisors LLC boosted its holdings in shares of Pfizer by 271.2% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 236,683 shares of the biopharmaceutical company’s stock valued at $5,842,000 after purchasing an additional 172,913 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 1.6%

Shares of NYSE:PFE opened at $24.00 on Wednesday. The firm has a market cap of $136.47 billion, a P/E ratio of 17.39, a P/E/G ratio of 0.89 and a beta of 0.57. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The business has a fifty day simple moving average of $23.14 and a 200 day simple moving average of $24.93.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the company earned $0.82 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.17%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.